Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Drug

TransThera Sciences and Allist Pharmaceuticals Launch Phase II Combination Study of TT-00973 and Furmonertinib in EGFR-Mutant NSCLC

Fineline Cube May 27, 2026
Company Deals

Fosun Pharma Invests RMB 220 Million in Hepa Thera, Becomes Second Largest Shareholder in Liver Disease Biotech

Fineline Cube May 27, 2026
Company Deals

Insilico Medicine and Human Longevity Spin-off HLFM Launch Multi-Million Dollar AI Foundation Model for Human Longevity Research

Fineline Cube May 27, 2026
Company Deals

Eli Lilly to Acquire Three Infectious Disease Companies for Up to $3.83 Billion – Expanding Vaccine Portfolio Beyond Traditional Therapeutics

Fineline Cube May 27, 2026
Company Deals

Shanghai Simpletouch Robot Files for Hong Kong IPO – Advancing Percutaneous Puncture Surgical Robotics Platform

Fineline Cube May 27, 2026
Policy / Regulatory

NMPA Issues Comprehensive Guidelines for Online Prescription Drug Retail, Mandating Human Pharmacist Review and AI Prescription Blocking

Fineline Cube May 26, 2026
Company Drug

Junshi Biosciences Completes Phase III NEOTORCH Study of Toripalimab in Perioperative NSCLC, Plans Regulatory Filing

Fineline Cube May 27, 2026
Company Deals Drug

TransThera Sciences and Allist Pharmaceuticals Launch Phase II Combination Study of TT-00973 and Furmonertinib in EGFR-Mutant NSCLC

Fineline Cube May 27, 2026
Company Deals

Everest Medicines and SPH Keyuan Ink MoU to Expand Xerava Distribution in China

Fineline Cube Apr 19, 2023

China-based Everest Medicines (HKG: 1952) has announced a Memorandum of Understanding (MoU) with a subsidiary...

Company Drug

Innovent Biologics Presents IBI351 Phase I Results at AACR Annual Meeting

Fineline Cube Apr 19, 2023

China-based Innovent Biologics (HKG: 1801) has published the results of a Phase I clinical study...

Medical Device Policy / Regulatory

National Center Reports Increase in Medical Device Adverse Event Reports for 2022

Fineline Cube Apr 19, 2023

The National Center for Adverse Event Monitoring has released its national annual report regarding the...

Policy / Regulatory

China’s NMPA, MPS, and NHC Announce Updates to Narcotics and Psychotropic Substances Catalog

Fineline Cube Apr 19, 2023

The National Medical Products Administration (NMPA), Ministry of Public Security, and National Health Commission have...

Company Deals

China Resources Biopharmaceutical Partners with Hefei Institute and Afana Bio for Joint Lab

Fineline Cube Apr 19, 2023

China Resources Biopharmaceutical Co., Ltd has announced a strategic partnership with the Hefei Comprehensive National...

Company Drug

XZenith Biopharm Completes Enrollment in Phase II Study for Proton Pump Inhibitor

Fineline Cube Apr 19, 2023

XZenith Biopharm, a Chinese company with minority ownership by Sihuan Pharma, has completed patient enrollment...

Company Drug

Adagene Inc. Presents Positive Interim Results for ADG126 at AACR Annual Meeting

Fineline Cube Apr 19, 2023

China-based Adagene Inc. (NASDAQ: ADAG) has announced interim results from its combination dose escalation studies...

Company Drug

BeiGene and SpringWorks Therapeutics Report Positive Phase Ib Results for Lifirafenib and Mirdametinib Combination

Fineline Cube Apr 18, 2023

China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) and SpringWorks Therapeutics Inc., (NASDAQ: SWTX) have...

Company Drug

HanchorBio Receives FDA Approval for Multi-Region Clinical Study of HCB101 Fusion Protein

Fineline Cube Apr 18, 2023

Taiwan-based HanchorBio has announced receiving the green light from the US FDA to conduct a...

Company Deals

Hainan’s Boao Lecheng Partners with Sonova to Advance Hearing Health Solutions in China

Fineline Cube Apr 18, 2023

The Boao Lecheng Medical Tourism Pilot Zone of Hainan Province has struck a strategic partnership...

Company Deals

Nanjing Chamlion Laser Technology Secures RMB 236 Million in Series B Financing for Dental 3D Printing

Fineline Cube Apr 18, 2023

Nanjing Chamlion Laser Technology Co., Ltd, a leading provider of dental metal 3D printing solutions...

Company Drug

HutchMed’s Elunate Receives NMPA Review for Second-Line Gastric Cancer Treatment

Fineline Cube Apr 18, 2023

China-based HutchMed (HKG: 0013, NASDAQ: HCM) has announced that the National Medical Products Administration (NMPA)...

Company Drug

HuidaGene Receives CDE IND Approval for Ophthalmology Gene Therapy HG004

Fineline Cube Apr 18, 2023

China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced receiving Investigational New Drug (IND) approval from...

Company Drug

CBMG’s C-CAR031 Shows Promising Results in Phase I Study for Hepatocellular Carcinoma

Fineline Cube Apr 18, 2023

China-based cell therapy specialist Cellular Biomedicine Group Inc. (CBMG) has published the results of the...

Company

CanSino Biologics Reports 2022 Revenue Drop and Increased Losses Amid COVID-19 Vaccine Market Shifts

Fineline Cube Apr 18, 2023

China-based vaccines specialist CanSino Biologics Inc., (HKG: 6185) has released its 2022 financial report, recording...

Company Deals

PackGene Secures Series C Financing to Boost AAV Innovation and Global Expansion

Fineline Cube Apr 18, 2023

China-based PackGene Biotech has announced the successful completion of a Series C financing round, securing...

Company Deals

Bioworkshops Secures RMB 100 Million in Series A Financing for Biologic Drug Development

Fineline Cube Apr 18, 2023

Bioworkshops, a Contract Development and Manufacturing Organization (CDMO) based in Suzhou and specializing in biologic...

Company Medical Device

Sinovation Medical’s SinoLITT System and Fiber Kit Gain NMPA Approval for Epilepsy Treatment

Fineline Cube Apr 18, 2023

Sinovation (Beijing) Medical Technology Co., Ltd has announced that its in-house developed magnetic resonance monitoring...

Company R&D

Merck and XtalPi Leverage Molecular Dynamics to Enhance Small-Molecule Crystallization

Fineline Cube Apr 17, 2023

German pharmaceutical giant Merck (NYSE: MRK) and China-based drug discovery solutions specialist XtalPi have published...

Company Drug

Neurophth Biotechnology Receives NMPA Approval for Phase I/II Gene Therapy Study

Fineline Cube Apr 17, 2023

Neurophth Biotechnology Ltd, a leading gene therapy specialist based in China, has announced that it...

Posts pagination

1 … 542 543 544 … 672

Recent updates

  • Junshi Biosciences Completes Phase III NEOTORCH Study of Toripalimab in Perioperative NSCLC, Plans Regulatory Filing
  • TransThera Sciences and Allist Pharmaceuticals Launch Phase II Combination Study of TT-00973 and Furmonertinib in EGFR-Mutant NSCLC
  • Fosun Pharma Invests RMB 220 Million in Hepa Thera, Becomes Second Largest Shareholder in Liver Disease Biotech
  • Changchun High & New Technology Industries Subsidiary Secures NMPA Approval for GenSci144, Novel Oral PKU Treatment Targeting SLC6A19 Transporter
  • Hengrui Pharmaceuticals Secures NMPA Clinical Approvals for Two Novel Anti-Tumor Drug Candidates SHR-5421 and HRS-1635
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Junshi Biosciences Completes Phase III NEOTORCH Study of Toripalimab in Perioperative NSCLC, Plans Regulatory Filing

Company Deals Drug

TransThera Sciences and Allist Pharmaceuticals Launch Phase II Combination Study of TT-00973 and Furmonertinib in EGFR-Mutant NSCLC

Company Deals

Fosun Pharma Invests RMB 220 Million in Hepa Thera, Becomes Second Largest Shareholder in Liver Disease Biotech

Company Drug

Changchun High & New Technology Industries Subsidiary Secures NMPA Approval for GenSci144, Novel Oral PKU Treatment Targeting SLC6A19 Transporter

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.